Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Akebia Therapeutics (Nasdaq: AKBA) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO John Butler will deliver a presentation on Thursday, January 16, 2024, at 7:30 AM PST, which will include updates on the Vafseo® (vadadustat) U.S. launch and other business matters. The conference is scheduled for January 13-16, 2025, in San Francisco. Interested parties can access the presentation webcast through the 'Investors' section of Akebia's website after the conference.

News Market Reaction – AKBA

-5.88%

-5.88% Session move

In the trading session that priced this news, AKBA declined 5.88%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Dec. 18, 2024 /PRNewswire/ -- Akebia Therapeutics^®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the 43^rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2024 at 7:30 AM PST. Among other business updates, Mr. Butler will discuss the Vafseo® (vadadustat) U.S. launch.  

A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com following the conference.

The J.P. Morgan Healthcare Conference will take place January 13-16, 2025 in San Francisco.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302334295.html

SOURCE Akebia Therapeutics, Inc.

FAQ

When will Akebia Therapeutics (AKBA) present at the 2024 J.P. Morgan Healthcare Conference?

Akebia Therapeutics will present on Thursday, January 16, 2024, at 7:30 AM PST.

What topics will be covered in AKBA's presentation at the J.P. Morgan Healthcare Conference?

The presentation will include updates on the Vafseo® (vadadustat) U.S. launch and other business updates.

How can investors access AKBA's J.P. Morgan Healthcare Conference presentation?

Investors can access the presentation webcast through the 'Investors' section of Akebia's website at https://ir.akebia.com following the conference.

What is the focus of Akebia Therapeutics' (AKBA) business?

Akebia Therapeutics is a biopharmaceutical company focused on improving the lives of people impacted by kidney disease.